A very high rate of activating mutations in Kras (>90%) exists in most human cancers of pancreas including the earliest stage of pancreatic intraepithelial neoplasia, common Kras mutations in pancreatic ductal adenocarcinoma are G12D, G12C, and G12V19,.20 Here, KRAS is linked to pancreatic neoplasm.